Y0000578
Paroxetine hydrochloride (anhydrous)
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Paroxetine hydrochloride, (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C19H20FNO3 · HCl
CAS Number:
Molecular Weight:
365.83
UNSPSC 코드:
41116107
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
paroxetine
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
Fc1ccc(cc1)[C@H]2[C@@H](CNCC2)COc3cc4c(cc3)OCO4.Cl
InChI
1S/C19H20FNO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7-8,10-12H2;1H/t14-,17-;/m0./s1
InChI key
GELRVIPPMNMYGS-RVXRQPKJSA-N
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Paroxetine hydrochloride (anhydrous) EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
가장 최신 버전 중 하나를 선택하세요:
Jie Liu et al.
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 33(4), 462-465 (2013-07-12)
To explore the efficacy of jieyu granule (JG) combined Paroxetine in treating refractory depression (RD) patients of yin deficiency inner heat syndrome (YDIHS). Seventy RD patients of YDIHS were randomly assigned to the experimental group (JG combined Paroxetine) and the
Yusuke Murata et al.
Journal of affective disorders, 150(3), 1209-1212 (2013-07-03)
Severe sleepiness and excess sleep duration, "Hypersomnia", induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience "Hypersomnia" during paroxetine treatment have good clinical response. The aim of this
Huang-Li Lin et al.
International clinical psychopharmacology, 28(6), 339-345 (2013-07-25)
This is a single-blind, parallel, flexible-dose study to compare the efficacy and tolerability of escitalopram and paroxetine in the treatment of patients with major depressive disorder. We recruited 399 patients from the outpatient clinics of five hospitals in northern Taiwan.
Mats B Humble et al.
BMC psychiatry, 13, 344-344 (2013-12-24)
The drug treatments of choice for obsessive-compulsive disorder (OCD) are serotonin reuptake inhibitors (SRIs). However, a correlation between the neuropeptide oxytocin in cerebrospinal fluid and the severity of OCD has previously been shown, and oxytocin and serotonin are interconnected within
Marek Krzystanek et al.
Pharmacological reports : PR, 65(3), 724-729 (2013-08-21)
Phospholipase D (PLD) plays a key role in a second messenger system producing phosphatidic acid, mediating, among others, serotonin 5-HT2 receptor activity. The aim of the study was to evaluate a possible effect of atypical antipsychotic drug, olanzapine (OLZ), and
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.